DDReg pharma

DELIVER BETTER DATA TO ENSURE FASTER APPROVAL
DDReg Pharma
Talk To Us

Blogs

Enhancing Accessibility to Contraceptives through Rx-to-OTC switch

Blogs, Regulatory /

In a world where women’s health and autonomy are of utmost importance, ensuring diverse and accessible contraceptive options has become a pressing priority. In response to evolving societal demands, the call for inclusive and non-prescriptive contraceptive solutions has emerged, allowing individuals to take control of their reproductive health, irrespective of their background or circumstances. The […]

Enhancing Accessibility to Contraceptives through Rx-to-OTC switch Read More »

The Future of Certificate of Suitability

Blogs, Pharmacovigilance, Regulatory /

The Certificate of Suitability (CEP) to the monographs of the European Pharmacopoeia (Ph. Eur.) plays a crucial role in verifying the quality standards of active pharmaceutical ingredients (APIs). Issued by the European Directorate for the Quality of Medicines (EDQM), the CEP serves as evidence that an API complies with the rigorous quality requirements outlined in

The Future of Certificate of Suitability Read More »

ICH: An Approach to Harmonizing Real World Data & Real World Evidence

Blogs, Regulatory /

The use of real-world data (RWD) and real-world evidence (RWE) in Life Sciences and Pharma is significantly gaining recognition for the value it brings in making enhanced regulatory decisions. The evaluation of pharmaceuticals throughout their development and lifecycle is a complex process that requires robust evidence to ensure their safety and effectiveness. Traditionally, randomized clinical

ICH: An Approach to Harmonizing Real World Data & Real World Evidence Read More »

US FDA: Resolving Disputes for Over-the-Counter Monograph Drugs

Blogs, Pharmacovigilance, Regulatory /

Over-The-Counter (OTC) monographs define the safety, effectiveness, and labelling of the active ingredients in OTCs. The US FDA released a guidance document that provides suggestions for industry and review staff on resolving scientific and medical disputes related to OTC monograph drugs. It describes the Center for Drug Evaluation and Research (CDER) formal dispute resolution (FDR)

US FDA: Resolving Disputes for Over-the-Counter Monograph Drugs Read More »

US FDA: Safety Reporting Requirements for Combination Products

Blogs, Pharmacovigilance, Regulatory /

In this new era, where different therapeutic realms converge, the emergence of combination products has revolutionized the healthcare landscape by providing more innovative treatment options to treat the unmet medical needs of patients. However, with great power comes great responsibility. Continuously monitoring these products and ensuring they are safe to use is paramount in order

US FDA: Safety Reporting Requirements for Combination Products Read More »

Challenges in Complex Generic Drug Development

Blogs, Pharmacovigilance, Regulatory /

Complex drugs add more value to patients compared to simple generics as they are capable of addressing unmet needs of patients for particular conditions. However, biopharmaceutical companies encounter distinctive hurdles when it comes to the advancement of complex generic drugs. These medications, known for their intricate characteristics or the requirement of additional clinical trials, necessitate

Challenges in Complex Generic Drug Development Read More »

US FDA: Keeping Up with the Momentum of Decentralized Clinical Trials

Blogs, Pharmacovigilance, Regulatory /

Decentralized clinical trials (DCTs) are evolving and gaining momentum within medical research as they increasingly incorporate state-of-the-art digital health technologies (DHTs). Indeed by way of DHTs, useful data for clinical trials can be collected, exchanged, transferred, and stored electronically and in a more efficient manner. In order to stay aligned with the momentum, regulatory agencies

US FDA: Keeping Up with the Momentum of Decentralized Clinical Trials Read More »

Innovative Medicines

Evaluating PRIME: A Pathway for Innovative Medicines

Blogs, Regulatory /

In various therapeutic areas where life expectancy is low, delayed market access to effective medicines has highlighted the need for expedited responses by regulators to support timely access to such priority medicines. The Priority Medicines Scheme, or PRIME, was implemented by the European Medicines Agency (EMA) to support and accelerate medicine development that targets unmet

Evaluating PRIME: A Pathway for Innovative Medicines Read More »

Clinical Practice

Enhancing Good Clinical Practice for the Evolving Clinical Trial Landscape

Blogs, Pharmacovigilance, Regulatory /

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) released a draft guideline update- the ICH E6 (R3)- that focuses on the application of Good Clinical Practice (GCP) to new trial designs, technological advancements, and enhancing a risk-based approach in clinical trials.The ICH E6 (R3) serves as an update to

Enhancing Good Clinical Practice for the Evolving Clinical Trial Landscape Read More »

FDA Compliance

How do Artwork Management Systems help maintain FDA compliance?

Artwork Management Services, Blogs, Regulatory /

The pharmaceutical industry is a highly regulated environment where investing in a reliable and efficient method for managing artwork can result in significant cost savings. Artwork management forms an integral part of regulatory affairs. The main objective of an artwork management system is to ultimately prevent product recall. Pharmaceutical companies invest significant time, money, and

How do Artwork Management Systems help maintain FDA compliance? Read More »